A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation
← catalyst calendarNCT07073950 · readout in 284 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Parexel.
Phase
Phase 4
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
56estimated
Sites
7
Countries
Germany, United Kingdom
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-24 | actual | When the study began enrolling |
| Primary completion | 2027-05-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-05-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Chronic Obstructive Pulmonary Disease
- Hyperinflation
Interventions
- Drug: Budesonide/Glycopyrronium/Formoterol Fumarate
- Drug: Placebo
- Device: Metered dose inhaler
Primary outcome
what the primary-completion date above is the date OFChange from baseline in left ventricular end diastolic volume indexed by body surface area (LVEDVi) measured by magnetic resonance imaging (MRI)
measured Up to 3 weeks
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed